Sunvozertinib
- Generic Name
- Sunvozertinib
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于既往经含铂化疗治疗时或治疗后出现疾病进展，或不耐受含铂化疗，并且经检测确认存在表皮生长因子受体（EGFR）20号外显子插入突变的局部晚期或转移性非小细胞肺癌（NSCLC）的成人患者。
- Associated Conditions
- -
- Associated Therapies
- -
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 120
- Registration Number
- NCT06563999
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 40
- Registration Number
- NCT06195189
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Si Chuan, China
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation (WU-KONG1)
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 315
- Registration Number
- NCT03974022
- Locations
- 🇮🇹
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST IRCCS, Meldola, Italy
🇯🇵Okayama University Hospital, Okayama-Shi, Japan
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath